Patents by Inventor Teresa Barlozzari
Teresa Barlozzari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8440626Abstract: The present invention provides antineoplastic peptides of formula I, I R1R2N-CHX-CO-A-B-D-E-(G)S-K wherein R1, R2, X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: GrantFiled: August 26, 2010Date of Patent: May 14, 2013Assignee: Abbott GmbH & Co. KGInventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weymann, Thomas Zierke
-
Publication number: 20130046077Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: ApplicationFiled: April 16, 2012Publication date: February 21, 2013Inventors: Bernd JANSSEN, Teresa BARLOZZARI, Andreas HAUPT, Thomas ZIERKE, Andreas KLING
-
Patent number: 8163698Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: GrantFiled: December 29, 2009Date of Patent: April 24, 2012Assignee: Abbott GmbH & Co. KGInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Publication number: 20110098235Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N-CHX-CO-A-B-D-E-(G)S-K?I wherein R1, R2, X, A, B, D, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: ApplicationFiled: August 26, 2010Publication date: April 28, 2011Applicant: ABBOTT GMBH & CO. KGInventors: Wilhelm AMBERG, Teresa BARLOZZARI, Harald BERNARD, Ernst BUSCHMANN, Andreas HAUPT, Hans-Guenther HEGE, Bernd JANSSEN, Andreas KLING, Helmut LIETZ, Kurt RITTER, Martina ULLRICH, Jürgen WEYMANN, Thomas ZIERKE
-
Patent number: 7807779Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO—A—B-D-E-(G)s-K wherein R1, R2, X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: GrantFiled: March 31, 2008Date of Patent: October 5, 2010Assignee: Abbott GmbH & Co. KGInventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weymann, Thomas Zierke
-
Publication number: 20100099843Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: ApplicationFiled: December 29, 2009Publication date: April 22, 2010Inventors: Bernd JANSSEN, Teresa BARLOZZARI, Andreas HAUPT, Thomas ZIERKE, Andreas KLING
-
Patent number: 7662786Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L ??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: GrantFiled: April 18, 2006Date of Patent: February 16, 2010Assignee: Abbott GmbH & Co. KGInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Publication number: 20080234205Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO—A—B-D-E-(G)s-K wherein R1, R2, X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: ApplicationFiled: March 31, 2008Publication date: September 25, 2008Applicant: Abbott GmbH & Co. KGInventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weymann, Thomas Zierke
-
Patent number: 7368528Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO-A-B-D-E-(G)s-K I wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: GrantFiled: July 11, 2005Date of Patent: May 6, 2008Assignee: Abbott GmbH & Co. KGInventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weyman, Thomas Zierke
-
Publication number: 20060270606Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L ??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: ApplicationFiled: April 18, 2006Publication date: November 30, 2006Applicant: Abbott GmbH & Co., KGInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Patent number: 7084110Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L,??(I) and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: GrantFiled: September 25, 2002Date of Patent: August 1, 2006Assignee: Abbott GmbH & Co., KGInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Publication number: 20060009392Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO-A-B-D-E-(G)s-K ??I wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: ApplicationFiled: July 11, 2005Publication date: January 12, 2006Applicant: Abbott GMBH & Co., KG.Inventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weymann, Thomas Zierke
-
Patent number: 6632795Abstract: The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of Formula I as defined herein in combination with paclitaxel, taxotere or modified taxane or taxoid analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.Type: GrantFiled: March 7, 2000Date of Patent: October 14, 2003Assignee: BASF AktiengesellschaftInventors: Teresa Barlozzari, Andreas Haupt
-
Publication number: 20030153505Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I,Type: ApplicationFiled: September 25, 2002Publication date: August 14, 2003Applicant: BASF AktiengesellschaftInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Patent number: 6534655Abstract: Chemical compounds that are derivatives of indeno[1,2-c]pyrazole are inhibitors of tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell proliferation is a factor. Compounds of this invention also inhibit the induction of vascular hyperpermeability and the associated formation of edema, ascites, and exudates.Type: GrantFiled: April 3, 2000Date of Patent: March 18, 2003Assignee: BASF AktiengesellschaftInventors: Lee D. Arnold, Yajun Xu, Teresa Barlozzari, Paul Rafferty, Michael Hockley, Allyson Turner
-
Patent number: 6458765Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L (I), and acid salts thereof, wherein A, B, D, E, F, G and K are &agr;-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: GrantFiled: July 18, 2000Date of Patent: October 1, 2002Assignee: BASF AktiengesellschaftInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Patent number: 6451834Abstract: Chemical compounds that are derivatives of indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole are inhibitors of tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in hyperproliferative, angiogenic or in vascular hyperpermeability processes. Thus, these chemical compounds can ameliorate disease states where tumor formation, metastasis, angiogenesis, vascular hyperpermeability or endothelial cell proliferation is a factor.Type: GrantFiled: April 3, 2000Date of Patent: September 17, 2002Assignee: BASF AktiengesellschaftInventors: Lee D. Arnold, Yajun Xu, Teresa Barlozzari
-
Patent number: 6323315Abstract: The present invention provides compounds of the formula where R1-R5 are each, independently, a hydrogen atom or a normal or branched C1-C6-alkyl group; A is a methionyl, phenylalanyl or phenylglycyl residue; n is 0 or 1; R6 is a hydrogen atom; and R7 is a carbocylic group, an aromatic group, a C1-C4-alkyl group, a pyridylalkyl group or a heterocyclic group. In another embodiment, R6 is benzyl or —C(O)OR8, where R8 is a C1-C6-alkyl group, and R7 is a heteroaromatic group, such as a 2-thiazolyl group.Type: GrantFiled: March 31, 2000Date of Patent: November 27, 2001Assignees: BASF Aktiengesellschaft, Arizona Board of RegentsInventors: George R. Pettit, Jayaram K. Srirangam, Michael D. Williams, Kieran P. M. Durkin, Teresa Barlozzari, Andreas Kling, Bernd Janssen, Andreas Haupt
-
Publication number: 20010018422Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IType: ApplicationFiled: January 8, 2001Publication date: August 30, 2001Applicant: BASF AktiengesellschaftInventors: Kurt Ritter, Bernd Janssen, Andreas Haupt, Andreas Kling, Teresa Barlozzari, Wilhelm Amberg
-
Publication number: 20010009901Abstract: The present invention provides antineoplastic peptides of formula I,Type: ApplicationFiled: January 9, 2001Publication date: July 26, 2001Applicant: BASF Aktiengesellschaft GermanyInventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weymann, Thomas Zierke